---
title: "MSD Moves Early as Protect Biotech Locks In Asia-Pacific Rights"
url: https://drugnews.com.tw/articles/2026-10-19-protect-pt401-canine-heart-gene-therapy-msd-en.html
date: 2026-10-19
lang: en
category: "商業分析系列"
tags: ["Protect Biotech","PT401","canine MMVD","gene therapy","MSD Animal Health"]
summary: "Dogs diagnosed with Stage B1 mitral valve disease are usually just monitored. In June 2026 MSD Animal Health invested in Rejuvenate Bio, while Protect Biotech had secured Asia-Pacific rights to the canine heart gene therapy PT401 in late 2024."
json: https://drugnews.com.tw/articles/2026-10-19-protect-pt401-canine-heart-gene-therapy-msd-en.json
publisher: Drugnews｜藥時事 (https://drugnews.com.tw/)
---
## 三句看懂

- Protect Biotech secured exclusive Asia-Pacific development, distribution and marketing rights to Rejuvenate Bio's canine heart gene therapy (PT401, formerly RJB-01) in late 2024, with a Stage B1 pilot study in Thailand and a Stage B2 pivotal trial planned in Taiwan.
- In June 2026 MSD Animal Health, with about US$6.354 billion in 2025 revenue, joined Rejuvenate Bio's US$6 million financing and began a strategic animal gene therapy R&D collaboration; public records do not show MSD acquiring PT401.
- The FDA fully approved Vetmedin (pimobendan) in late 2025 to delay congestive heart failure in Stage B2 MMVD dogs, extending median time to the primary event from 766 to 1,228 days, leaving Stage B1 without a disease-modifying therapy.

## 關鍵數字（附來源）

| 項目 | 數值 | 日期 | 來源 |
|---|---|---|---|
| MSD Animal Health 2025 年營收 | 63.54 億美元 | 2026-02-26 | https://www.merck.com/wp-content/uploads/sites/124/2026/02/MRK-12.31.2025-10K-FINAL.pdf |
| BRAVECTO 產品線 2025 年銷售額 | 11 億美元 | 2026-02-26 | https://www.merck.com/wp-content/uploads/sites/124/2026/02/MRK-12.31.2025-10K-FINAL.pdf |
| Rejuvenate Bio 募資金額（MSD Animal Health 參與） | 600 萬美元 | 2026-06 | https://rejuvenatebio.com/press-releases/rejuvenate-bio-announces-6-million-financing-and-strategic-rampd-collaboration-with-merck-animal-health |
| 寶泰生醫取得犬心臟基因療法亞太獨家權利時間 | 2024 年底 時間 | 2024-12 | https://www.taiwan-healthcare.org/en/news-detail?id=0socwy3nnjfogkkr |
| MMVD 占北美犬心臟病病例比例 | 75 % | 2019 | https://pmc.ncbi.nlm.nih.gov/articles/PMC6524084/ |
| 全球獸醫心臟醫療市場 2025 年規模 | 35.6 億美元 | 2025 | https://www.novaoneadvisor.com/report/veterinary-cardiology-market |
| 全球獸醫心臟醫療市場 2035 年預估規模 | 80 億美元 | 2035 | https://www.novaoneadvisor.com/report/veterinary-cardiology-market |
| 亞太獸醫心臟醫療市場 2025 年規模 | 6.37 億美元 | 2025 | https://www.grandviewresearch.com/horizon/outlook/veterinary-cardiology-market/asia-pacific |
| 全球伴侶動物心臟藥物市場 2033 年預估 | 37.3 億美元 | 2033 | https://www.grandviewresearch.com/industry-analysis/companion-animal-cardiac-drugs-market-report |
| 亞太伴侶動物心臟藥物市場 2033 年預估 | 8.518 億美元 | 2033 | https://www.grandviewresearch.com/horizon/outlook/companion-animal-cardiac-drugs-market/asia-pacific |
| Pimobendan 2024 年占全球伴侶動物心臟藥物市場比例 | 41.17 % | 2024 | https://www.grandviewresearch.com/industry-analysis/companion-animal-cardiac-drugs-market-report |
| EPIC 研究主要事件中位時間（pimobendan 組） | 1228 天 | 2025 | https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-drug-delay-congestive-heart-failure-dogs |
| EPIC 研究主要事件中位時間（安慰劑組） | 766 天 | 2025 | https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-drug-delay-congestive-heart-failure-dogs |
| Rejuvenate Bio RJB-01 犬先導安全研究犬數 | 18 隻 | 2023 | https://www.businesswire.com/news/home/20230518005611/en/Rejuvenate-Bio-Announces-Data-for-Gene-Therapy-RJB-01-in-Mitral-Valve-Disease-at-2023-Meeting-of-the-American-Society-of-Gene-and-Cell-Therapy-ASGCT |
| MSD Animal Health 擴建美國設施投資 | 8.95 億美元 | 2026-02-26 | https://www.merck.com/wp-content/uploads/sites/124/2026/02/MRK-12.31.2025-10K-FINAL.pdf |

The story of canine myxomatous mitral valve disease (MMVD) often begins in a clinic with no obvious alarm. The dog is still eating, playing, and tugging eagerly at the leash. Then the veterinarian places a stethoscope on its chest and hears something that should not be there: a heart murmur. The disease has already started, even though everyday life looks exactly the same as it did yesterday.

For owners, one of the hardest things to hear is: "For now, we monitor." Ultrasound already shows valvular degeneration, but the heart has not enlarged and the dog has no obvious symptoms. Under the current staging system, this is Stage B1. For most dogs, pimobendan does not become core therapy until cardiac enlargement pushes the disease into Stage B2. That leaves a clinically visible but therapeutically empty interval between diagnosis and treatment - a period in which everyone can see the disease, but can only wait for it to progress.

In June 2026, that waiting period brought a global animal-health major into the story. MSD Animal Health, which generated US$6.354 billion in 2025 revenue and built BRAVECTO into a US$1.1 billion long-acting franchise, participated in Rejuvenate Bio's US$6 million financing and entered a strategic R&D collaboration in animal gene therapy. Canine cardiac gene therapy has not yet completed a pivotal trial, yet MSD has already taken a seat at the table. [1][2]

Protect Biotech moved even earlier. In late 2024, the company secured exclusive Asia-Pacific rights to develop, distribute, and market the relevant canine cardiac gene therapy, then placed a Stage B1 pilot study in Thailand and subsequent regulatory development in Taiwan on a coordinated regional path. [3][4] Rejuvenate Bio provides the dual-gene AAV technology, while Protect Biotech is responsible for translating it into clinical and regulatory evidence in Asian dogs. On the other side, MSD has moved closer to Rejuvenate Bio through investment and a strategic R&D collaboration. [5] Public disclosures do not indicate that MSD has acquired PT401, nor do they disclose the full three-party economics. After more than two decades without a commercial breakthrough in human cardiac gene therapy, could the next step come first from a dog still happily out for a walk?

![Figure 1. Starting from the Stage B1 treatment gap in canine](https://drugnews.com.tw/assets/articles/protect-pt401-canine-heart-gene-therapy-msd-en/figure-01.png)
*Figure 1. Starting from the Stage B1 treatment gap in canine MMVD, the figure maps PT401's single-dose/low-frequency intervention concept and the two overlapping bilateral relationships: Rejuvenate Bio-Protect Biotech Asia-Pacific licensing and Rejuvenate Bio-MSD investment/R&D collaboration. Together, they define a potential path toward commercialization.*

## Inside an $8 Billion Market, the Quietest White Space Is Stage B1

A heart murmur is only the first clue. If ultrasound then shows the mitral valve progressively thickening and deforming until it can no longer close completely between the left atrium and left ventricle, part of the blood flows backward with every contraction. The dog may still look energetic, but the heart is already compensating by working harder.

That compensation can last for some time, but the biological cost accumulates. The left atrium and left ventricle gradually enlarge as metabolic stress, neurohormonal activation, and fibrosis increase. By the time fluid accumulates in the lungs, owners may finally see coughing, rapid breathing, reduced activity, fainting, or overt congestive heart failure. At that point, care can shift quickly from routine follow-up to multidrug therapy, intensive monitoring, and even middle-of-the-night emergency visits.

This is not an uncommon clinical scenario. According to the ACVIM consensus guidelines, roughly 10% of dogs seen in primary veterinary practice have some form of heart disease. MMVD is the most common category and accounts for about 75% of canine heart disease cases in North America. The disease is concentrated in middle-aged and older small-breed dogs, including Cavalier King Charles Spaniels, Dachshunds, Poodles, Chihuahuas, and Pomeranians. [6]

That concentration is unusually helpful for therapeutic development. Human heart failure is highly heterogeneous; canine MMVD follows a more consistent core disease course and has a clear A, B1, B2, C, and D staging system. From auscultation to radiography and echocardiography, investigators can track when the heart enlarges, when pulmonary edema develops, and how much time a therapy actually adds before the next disease event.

| Disease Stage | Clinical Status                                  | Current Standard Management                 | Industry Implication                                                         |
|---------------|--------------------------------------------------|---------------------------------------------|------------------------------------------------------------------------------|
| Stage A       | High risk; no structural abnormality             | Routine screening and auscultation          | Screening and prevention entry point                                         |
| Stage B1      | Valvular disease present; no cardiac enlargement | Echocardiography and periodic monitoring    | Diagnosed population already exists; standard drug therapy is largely absent |
| Stage B2      | Cardiac enlargement; no heart failure yet        | Pimobendan                                  | Established chronic prescription market                                      |
| Stage C       | Pulmonary edema; respiratory distress            | Inotropes, diuretics, and multidrug therapy | Emergency care, hospitalization, and high care burden                        |
| Stage D       | Refractory heart failure                         | Individualized rescue treatment             | High cost and limited therapeutic flexibility                                |

*Table 1. Major clinical stages and treatment approaches in canine myxomatous mitral valve disease (MMVD).*

Pull the lens back from a single clinic to the industry, and the disease course sits inside a market that is still expanding. Nova One Advisor [7] estimates the global veterinary cardiology market at approximately US$3.56 billion in 2025, rising to US$8.0 billion by 2035, a CAGR of 8.44%.

One of the faster-growing regions is the Asia-Pacific market covered by Protect Biotech's rights. Grand View Research estimates the Asia-Pacific veterinary cardiology market at approximately US$637 million in 2025, with a 2026-2033 CAGR of 11.06%. [8]

Narrow the scope to companion-animal cardiac drugs, and the global market is estimated at about US$1.99 billion in 2025 and US$3.73 billion by 2033, representing an 8.13% CAGR. In Asia-Pacific, the market is projected to grow from US$392.7 million in 2025 to US$851.8 million in 2033, a CAGR of 10.5%. Canine products account for 64.73% of the global cardiac-drug market. [9][10]

| Market Scope                                | Current Market Size | Mid-/Long-Term Size | Growth      |
|---------------------------------------------|---------------------|---------------------|-------------|
| Global veterinary cardiology market         | US$3.56B (2025)    | ~US$8.0B (2035)    | CAGR ~8.44% |
| Asia-Pacific veterinary cardiology market   | ~US$637M (2025)    | ~US$1.46B (2033)   | CAGR 11.06% |
| Global companion-animal cardiac drugs       | US$1.99B (2025)    | US$3.73B (2033)    | CAGR 8.13%  |
| Asia-Pacific companion-animal cardiac drugs | ~US$392.7M (2025)  | US$851.8M (2033)   | CAGR 9.4%   |

*Table 2. Global and Asia-Pacific veterinary cardiology and companion-animal cardiac-drug markets.*

These market figures should not be added together. The drug market is closer to the revenue pool a new therapy could directly capture; the broader veterinary cardiology market also includes diagnostics, imaging, specialty visits, administration, and follow-up. Looking at both scopes together is useful because it shows that the patients and the spending already exist - but much of today's spending is concentrated on monitoring and treatment from Stage B2 onward.

That brings the question back to Stage B1. Veterinarians have already identified the disease, and owners are already returning for follow-up. What is missing is a disease-modifying therapy that can safely delay progression and earn broad guideline acceptance. Whether B1 can move from a monitoring stage to a treatment stage will determine whether PT401 captures a small slice of existing spending or creates a prescription market where none exists today.

![Figure 2. Canine MMVD market structure, disease staging, and](https://drugnews.com.tw/assets/articles/protect-pt401-canine-heart-gene-therapy-msd-en/figure-02.png)
*Figure 2. Canine MMVD market structure, disease staging, and the Stage B1 treatment gap. The diagnosed population, diagnostics, and follow-up already exist; the key question for a new therapy is whether it can intervene safely before cardiac enlargement begins.*

## Pimobendan Proved Canine Cardiology Can Build a Major Drug Franchise

To understand the commercial opportunity in Stage B1, it helps to look first at what happened in Stage B2. Pimobendan increases cardiac contractility, dilates blood vessels, and reduces cardiac workload, making it one of the most important advances in veterinary cardiology over the past decade. The large EPIC study tested it in Stage B2 dogs with cardiac enlargement but no heart failure and showed that treatment could delay congestive heart failure or cardiac-related death.

In late 2025, the U.S. FDA fully approved Vetmedin (pimobendan) to delay congestive heart failure in dogs with Stage B2 MMVD. In the study, median time to the primary event increased from 766 days to 1,228 days - a difference of about 15.6 months. [11][12]

Fifteen-plus months is just a number in a dataset. In a dog's life, it can mean another summer, another stretch of easy walks, or more than a year before a family has to face pulmonary edema, emergency care, and intensive treatment. In practical terms, what pimobendan sells to owners is measurable healthy time.

Clinical value also translated into market position. Grand View Research estimates that pimobendan accounted for 41.17% of the global companion-animal cardiac-drug market in 2024. This is a third-party market estimate, not company-reported sales, but it still illustrates the point clearly: a product that enters guidelines, accumulates long-term evidence, and earns veterinarian trust can become the anchor of an entire category. [9]

That success also draws a clear boundary for PT401. If a new therapy only replaces pimobendan in Stage B2, it must compete head-on with a drug that has mature evidence, strong veterinarian familiarity, and manageable pricing. If it can safely identify high-risk Stage B1 dogs and push disease progression further out, however, it creates an additional treatment period before prescriptions typically begin today. The first market PT401 is trying to win sits between those two stages.

> The next major opportunity is to give Stage B1 dogs a treatment option after diagnosis, rather than waiting until the heart enlarges.

![Figure 3. The EPIC Study and FDA approval established pimobe](https://drugnews.com.tw/assets/articles/protect-pt401-canine-heart-gene-therapy-msd-en/figure-03.png)
*Figure 3. The EPIC Study and FDA approval established pimobendan as a core Stage B2 therapy and showed that delaying disease events can create a mature prescription market in canine cardiology.*

## PT401 Aims to Move Treatment Earlier - and Extend Healthy Time

Only at this point does PT401 fully enter the story. The asset for which Protect Biotech holds Asia-Pacific rights was originally developed by Rejuvenate Bio as RJB-01. Instead of following the conventional inotrope pathway, it is designed to make the dog's own cells continuously produce two therapeutic proteins.

PT401 uses an AAV vector to deliver both FGF21 and soluble TGF-beta receptor type 2 (sTGFbetaR2). FGF21 is associated with energy metabolism, lipid utilization, and cellular stress regulation; sTGFbetaR2 is intended to intercept part of the TGF-beta signaling pathway to reduce pathological fibrosis and adverse cardiac remodeling. [13]

In simpler terms, one arm is designed to help the myocardium manage chronic metabolic stress, while the other is intended to slow the process by which the heart becomes stiffer and enlarged under chronic injury. AAV acts as the delivery vehicle, carrying both therapeutic instructions into cells. If expression is stable, a single administration could allow the dog to continue producing the therapeutic proteins over time.

Durability is both the attraction and the development risk. With a single-dose AAV therapy, treatment cannot be switched off immediately the way an oral drug can, making target biology, the existing safety foundation, dose window, and long-term monitoring especially important. Early data can provide only preliminary safety signals; later studies still need to show that immune reactions, liver effects, and other adverse events are manageable, and that therapeutic-protein expression is sufficient, stable, and durable. Vector potency, batch consistency, and manufacturing quality will also remain central all the way through clinical development and commercialization.

Rejuvenate Bio has completed a pilot safety study in 18 dogs. According to company-reported data, RJB-01 therapeutic proteins remained expressed for nearly three years, with an encouraging preliminary safety profile. In dogs receiving RJB-01 as an add-on to pimobendan, disease progression was delayed by roughly 200 days versus historical controls, with a signal of improved left-atrial dimensions. [14] These findings suggest that RJB-01/PT401 may offer more than durability: as an add-on therapy, it could further slow cardiac remodeling and disease progression on top of pimobendan. The study was small and relied on historical controls, however, so the effect still requires confirmation in a randomized pivotal trial.

For the product itself, PT401 can currently be broken into four key elements. First, it is designed as a single-dose therapy. Second, a pivotal Stage B2 trial in Taiwan is intended to generate efficacy and safety evidence closer to registration. Third, a Stage B1 pilot study in Thailand is exploring the opportunity to intervene earlier. Fourth, treatment will still require pre-dose risk stratification, cardiac imaging, specialty centers, and long-term follow-up. Only if all four pieces work together can PT401 evolve from an expensive injection into an executable disease-management product.

| Treatment Approach     | Best-Fit Stage                               | Key Advantages                                                                  | Key Limitations                                                                                             |
|------------------------|----------------------------------------------|---------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| Pimobendan             | Stage B2 onward                              | Robust trial evidence and established clinical adoption; delays heart failure   | Not standard in B1; chronic dosing; does not directly address valve degeneration                            |
| Symptom-control drugs  | Stages C-D                                   | Rapid control of pulmonary edema and hemodynamic symptoms                       | Multidrug burden and long-term monitoring; mainly treats consequences rather than early disease progression |
| Valve repair           | After structural disease becomes significant | Directly reduces regurgitation                                                  | Expensive, invasive, and limited to a small number of centers                                               |
| Cell therapy           | Early research or specialist treatment       | May modulate inflammation, fibrosis, and tissue repair simultaneously           | Manufacturing consistency, persistence, and durability remain uncertain                                     |
| PT401-like AAV therapy | High-risk B1 to early B2                     | Targeting one-time administration, durable expression, and earlier intervention | Immunogenicity, dose, redosing, manufacturing, price, and long-term safety remain to be proven              |

*Table 3. Comparative strengths, limitations, and positioning of current and next-generation therapies for canine MMVD.*

> PT401 is competing for a block of time medicine does not yet cover: the dog is diagnosed, but the heart has not enlarged.

![Figure 4. PT401 uses a dual-gene AAV approach to move the in](https://drugnews.com.tw/assets/articles/protect-pt401-canine-heart-gene-therapy-msd-en/figure-04.png)
*Figure 4. PT401 uses a dual-gene AAV approach to move the intervention window toward high-risk Stage B1/early Stage B2, with a product profile built around single-dose or low-frequency administration, durable expression, and a longer treatment window.*

## How Much Market Could PT401 Capture? Start With Dogs Treated

Once the mechanism story is clear, the next question is much more practical: how large a business could an unapproved canine cardiac AAV therapy become when there is no true comparable product to benchmark? There is no reliable single-point answer today, and forcing one precise sales number would hide more risk than it clarifies. A more disciplined approach is to separate market share, treatment price, and the number of dogs treated each year.

Start with the Asia-Pacific market covered by Protect Biotech's rights. The Asia-Pacific companion-animal cardiac-drug market is projected to reach US$851.8 million in 2033. If PT401 captures 5%, 10%, or 15% of market spending at commercial maturity, annual product sales would be approximately US$42.59 million, US$85.18 million, and US$127.7 million, respectively. [10]

That analysis still uses existing drug spending as the denominator. The larger upside case comes from Stage B1, where dogs today mainly generate ultrasound and follow-up spending. If PT401 can identify high-risk animals and demonstrate in controlled trials that earlier intervention delays cardiac enlargement, medical spending could expand from monitoring alone to include an actual treatment.

The next step is to convert revenue into dogs treated. Assuming a treatment price of US$5,000-US$7,500 per dog purely for sensitivity analysis, US$50 million in annual sales would require roughly 6,700-10,000 dogs treated per year; US$100 million would require about 13,300-20,000 dogs. If 100,000 dogs were treated globally each year, product revenue could reach US$500 million-US$750 million.

Demand alone will not determine the outcome. AAV antibodies, immune effects and long-term safety, the number of hospitals capable of administering the therapy, owner willingness and ability to pay, manufacturing cost, and duration of benefit will all limit real-world penetration. A one-time, high-priced therapy can generate greater revenue density, but only if tens of thousands of dogs can be correctly selected, successfully treated, and followed for years with an acceptable benefit-risk profile.

At the global level, the companion-animal cardiac-drug market is projected to reach US$3.73 billion in 2033. A 5% share would equal roughly US$187 million in annual sales, while 10% would equal about US$373 million. Applying a 3x-5x product-sales multiple to a mature-asset scenario implies a product-level value of approximately US$560 million-US$1.87 billion. This is not a disclosed valuation for Protect Biotech or any other company, and it does not adjust for clinical failure risk, development timelines, manufacturing costs, or profit-sharing among partners. It is simply a way to frame the potential order of magnitude if the asset succeeds.

How much of that value ultimately accrues to Protect Biotech will depend on licensing economics, manufacturing costs, channel margins, and future partnerships. If the company participates not only through regional drug rights but also through diagnostics, veterinary networks, and longitudinal data capture, revenue could extend beyond drug sales into testing, treatment services, licensing, and disease management. That is why the market scenarios need to be read together with the bilateral relationships and the underlying rights structure.

> Pimobendan turned Stage B2 into a mature prescription market; if PT401 succeeds, the new opportunity is a treatment option in Stage B1 and a therapy that begins earlier in the disease course.

![Figure 5. Potential PT401 penetration scenarios across the f](https://drugnews.com.tw/assets/articles/protect-pt401-canine-heart-gene-therapy-msd-en/figure-05.png)
*Figure 5. Potential PT401 penetration scenarios across the future Asia-Pacific and global cardiac-drug markets.*

## Why Did MSD Move Early? The Answer Is in BRAVECTO's $1.1 Billion Franchise

The market scenarios frame the potential scale, but they do not answer the more important question: why MSD? One clue comes from a flea-and-tick drug. MSD first extended BRAVECTO's dosing interval to 12 weeks, then introduced BRAVECTO Quantum, a veterinarian-administered single injection that provides one year of protection. In 2025, the BRAVECTO franchise generated US$1.1 billion in sales.

That commercial history shows that the animal-health market will pay for lower dosing frequency, veterinarian involvement, and better adherence. PT401 addresses heart disease and gene therapy, with far higher clinical and manufacturing risk than a flea-and-tick drug, so the two products cannot be directly compared on efficacy or probability of success. But low-frequency dosing, administration in a veterinary center, and long-term follow-up are commercial patterns MSD already understands.

Scale determines whether that model can be carried globally. MSD Animal Health generated about US$6.4 billion in 2025 revenue and sells products in roughly 150 markets. The company has also announced US$895 million in U.S. facility investments to expand biologics, manufacturing, and R&D capacity. [15] Those resources span global regulatory capabilities, quality systems, supply chain, and veterinary channels - exactly the capabilities that are hardest for an AAV program to build as it moves from early data toward a commercial product.

If PT401 reaches the market, the clinical workflow will need to be built alongside it: identify high-risk dogs within Stage B1, complete pre-treatment assessment, administer therapy at specialty centers, and then track imaging, safety, and disease progression. Rejuvenate Bio brings the technology engine; Protect Biotech is responsible for the Asia-Pacific clinical and regulatory path. If MSD deepens its involvement later, it has the infrastructure to replicate a proven workflow across multiple countries.

| MSD Animal Health Positioning                               | Established Capability                                             | Potential Relevance to PT401                                           |
|-------------------------------------------------------------|--------------------------------------------------------------------|------------------------------------------------------------------------|
| ~US$6.4B animal-health revenue in 2025                     | Global animal-health commercial platform                           | Capital and organizational scale to support a new category             |
| BRAVECTO annual sales of US$1.1B                           | Long-acting products, brand, and veterinary channels               | Shows that low-frequency dosing can support a billion-dollar franchise |
| BRAVECTO Quantum: one injection per year                    | Veterinarian-administered injection and long-term management model | Shares commercial elements with PT401's potential treatment setting    |
| US$895M investment in manufacturing and R&D expansion      | Biologics manufacturing, quality systems, and scale-up capability  | Provides infrastructure needed for global commercialization            |
| Products in ~150 markets                                    | Global regulatory, supply-chain, and sales network                 | Can amplify regional clinical signals into global markets              |
| Health management, identification, and connected monitoring | Data and longitudinal disease management                           | Supports post-treatment follow-up and real-world data generation       |

*Table 4. MSD Animal Health's strategic footprint and its potential relevance to PT401.*

MMVD is therefore a compelling test bed. The patient population is large and relatively concentrated, echocardiography and disease staging are well established, and progression can be tracked. Pimobendan has also educated veterinarians and owners around a simple value proposition: paying today to delay heart failure tomorrow. MSD does not need to build the canine-cardiology market from scratch. The question is whether gene therapy can extend that value proposition into Stage B1 and ultimately become a scalable new product category.

> What MSD is buying today is time and optionality before the next data readout.

![Figure 6. Strategic footprint of MSD Animal Health’s bet on ](https://drugnews.com.tw/assets/articles/protect-pt401-canine-heart-gene-therapy-msd-en/figure-06.png)
*Figure 6. Strategic footprint of MSD Animal Health’s bet on RJB-01/PT401 and MMVD.*

## Protect Biotech Secured Its Asia-Pacific Position Before MSD Entered

The final question is Protect Biotech's role. It is easy to shorthand the current setup as "Protect Biotech working with MSD," but the public record shows a more precise structure: two bilateral relationships intersect at Rejuvenate Bio, with Protect Biotech and MSD occupying different positions.

The first relationship is the Asia-Pacific license between Protect Biotech and Rejuvenate Bio. In late 2024, Protect Biotech secured exclusive rights across Asia-Pacific to develop, distribute, and market the relevant canine cardiac gene therapy, taking responsibility for regional clinical development and market advancement. [3]

The second relationship is between Rejuvenate Bio and MSD. MSD participated in the financing and entered a strategic R&D collaboration around an animal gene-therapy program. [2][5]

The boundary needs to be explicit: public disclosures do not indicate that MSD has acquired PT401, and they do not disclose the full three-party rights or economics. Protect Biotech's advantage comes from sequencing. By the time MSD began evaluating Rejuvenate Bio's platform, Protect Biotech already held the Asia-Pacific rights and had started building regional data. If manufacturing and clinical evidence strengthen, the strategic value of that regional position could rise with them.

| Partner           | Core Assets                                                                                          | Current Role                                                               |
|-------------------|------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Rejuvenate Bio    | Dual-gene AAV, platform technology, early canine data                                                | Validate whether the technology can become a consistent product            |
| Protect Biotech   | Exclusive Asia-Pacific rights, Taiwan and Thailand clinical programs, regional veterinary network    | Translate an overseas technology into Asian regulatory and market evidence |
| MSD Animal Health | Capital, manufacturing, global regulatory capabilities, channels, and long-acting product experience | Assess whether the product can be scaled, approved, and expanded globally  |

*Table 5. Strategic positioning of Protect Biotech, MSD Animal Health, and Rejuvenate Bio.*

Thailand and Taiwan represent two parallel, complementary clinical paths. The Stage B1 MMVD pilot led by Protect Biotech and conducted at Chulalongkorn University in Thailand is designed to explore safety, dog selection, and early efficacy signals for earlier intervention. Taiwan is planned as a pivotal Stage B2 MMVD trial testing PT401 as add-on therapy to pimobendan, generating the efficacy, safety, and regulatory evidence closest to a first registration package. In other words, Stage B2 is currently the core evidence path toward initial approval, while Stage B1 is the incremental opportunity to move treatment earlier. Whether MSD moves closer will depend on whether the program can be manufactured at scale and translated into a global product.

If that path works, Protect Biotech's economics could extend beyond PT401 product sales alone. A high-value AAV therapy requires cardiac ultrasound, risk stratification, pre-treatment assessment, certified treatment centers, and years of imaging and safety follow-up. If Protect Biotech can connect its therapeutics with Mouteng's diagnostic capabilities, veterinary-hospital network, and data feedback loop, it could participate across drug sales, testing, treatment services, licensing, and disease management.

The first product forces the company to build veterinarian education, trial centers, regulatory processes, and data systems. Once those capabilities exist, the next oncology, autoimmune, or age-related chronic-disease asset can reuse part of the same infrastructure. Platform value only becomes real when a second and third asset can move through the same system.

> The first product proves the pathway can work. The second determines whether the same Asia-focused translation and commercialization engine can be reused - and whether the platform deserves a premium.

![Figure 7. Strategic positioning of Protect Biotech, MSD Anim](https://drugnews.com.tw/assets/articles/protect-pt401-canine-heart-gene-therapy-msd-en/figure-07.png)
*Figure 7. Strategic positioning of Protect Biotech, MSD Animal Health, and Rejuvenate Bio. Tech sourcing from Rejuvenate Bio, unique position of Protect’s securing exclusive Asia-Pacific rights and potential global marketing capability from MSD Animal Health.*

## Protect Biotech's Re-Rating Case Has to Clear Four Data Gates

The first gate is execution: the Asian studies need to operate in the real world. The market needs to see first-dog dosing, enrollment velocity, staging quality, and follow-up completion. IACUC approval only means a study is allowed to start; it does not generate safety or efficacy data. Even first-dog dosing simply moves the program from paper into the clinic.

The second gate is safety and durable expression. Stage B1 dogs are still living normal lives, so tolerance for severe risk is much lower than in end-stage heart failure. The therapy must show that immune reactions, liver effects, and other adverse events can be managed, and that FGF21 and sTGFbetaR2 expression is sufficient, reproducible, and durable.

The third gate is disease progression. Imaging signals can support the mechanism, but premium pricing and broad adoption will require harder evidence: do Stage B1 dogs enter B2 later, do Stage B2 dogs develop pulmonary edema later, and do emergency visits, hospitalizations, and cardiac-related deaths decline? Those event-based endpoints convert "it looks active" into "how much time does it actually buy the dog?"

The fourth gate is global productization. AAV purity, potency, full-capsid ratio, batch consistency, cold chain, and manufacturing cost all need to reach commercial specifications. At the same time, investors will watch whether MSD moves into manufacturing, late-stage development, or global rights, and how Protect Biotech's Asia-Pacific economics ultimately materialize - through direct commercialization, co-commercialization, sublicensing, or royalties.

Each gate that is cleared gives the market a reason to reclassify Protect Biotech: from a regional license holder, to a company capable of executing companion-animal drug trials, and then to an Asia-Pacific regulatory and commercialization node. Only when the same engine can be reused by a second and third asset does the idea of a "serious-disease pet-health platform" become a verifiable corporate capability rather than a narrative.

![Figure 8. Protect Biotech's next stage of value depends on f](https://drugnews.com.tw/assets/articles/protect-pt401-canine-heart-gene-therapy-msd-en/figure-08.png)
*Figure 8. Protect Biotech's next stage of value depends on four layers of evidence: execution of the Asian studies, safety and durable expression, modification of disease progression, and the ability to reach global commercialization.*

## Conclusion: The First Blockbuster Cardiac Gene Therapy May Walk Out of a Veterinary Clinic Wearing a Collar

Human cardiac gene therapy has spent more than two decades wrestling with patient heterogeneity, vector delivery, long-term endpoints, and high development costs. Canine MMVD offers a different set of conditions: a concentrated disease population, identifiable high-risk breeds, mature imaging and staging, and a disease course that can be observed over a more practical timeframe. Existing drugs, specialty veterinary centers, and owner spending are already in place, yet Stage B1 still contains a stretch of time with no disease-modifying therapy.

That treatment gap helps explain why MSD is willing to move closer early.

MSD has already shown through BRAVECTO that a long-acting animal-health product can become a billion-dollar franchise. Rejuvenate Bio brings the dual-gene AAV technology. Protect Biotech secured the Asia-Pacific rights before a global major moved in and has placed Thailand and Taiwan on the clinical and regulatory path.

From here, every party is waiting for the same thing: data.

The answer still comes back to the clinic. The dog with the newly detected heart murmur may still be eating normally and waiting by the door for a walk, with a heart that has not yet enlarged enough to enter Stage B2. Technology platforms, global channels, and market size mean little to that dog and its owner. The immediate question is much simpler: if we intervene now, can we make progression come later?

If controlled studies show that PT401 can do that, Stage B1 could move from "come back for another checkup" to a stage with an actual treatment option. A single-dose or low-frequency gene therapy could then begin to take on the profile of a several-hundred-million-dollar product. For Protect Biotech, the Thailand and Taiwan data will determine whether it holds merely a regional license or a pathway that global companion-animal innovators are willing to use when entering Asia.

PT401 does not need to be described as a therapy that makes an aging valve young again.

What it actually has to prove is that it can safely buy back more healthy time: delay pulmonary edema, emergency visits, and multidrug therapy, and preserve more days when the dog can still walk, sit in the sun, and stay close to its family.

Early imaging signals will not be enough. Randomized controls, disease events, long-term safety, and a scalable manufacturing process all have to work before the story can become a commercial product.

The commercialization pathway that human cardiac gene therapy has not yet closed after 20 years may indeed be completed first by a dog wearing a collar. How far that dog can go, however, will be answered by PT401's next set of data.

Disclaimer | This article is based on publicly available information and research materials provided as of August 14, 2026. It is intended solely for industry analysis and does not constitute investment advice. Preclinical and early clinical findings do not guarantee ultimate efficacy, regulatory approval, or commercialization. This article is industry and company analysis and does not constitute investment or medical advice.

## References

1. Merck | 2025 Form 10-K: Animal Health Revenue, BRAVECTO Sales, and Global Operations｜merck.com｜2026-10-08｜https://www.merck.com/wp-content/uploads/sites/124/2026/02/MRK-12.31.2025-10K-FINAL.pdf
2. Rejuvenate Bio Announces $6 Million Financing and Strategic R&D Collaboration with Merck Animal Health | Rejuvenate Bio｜rejuvenatebio.com｜2026-10-08｜https://rejuvenatebio.com/press-releases/rejuvenate-bio-announces-6-million-financing-and-strategic-rampd-collaboration-with-merck-animal-health
3. Breakthrough in Pet Healthcare Across Asia-Pacific: Protect Biotech Partners with Rejuvenate Bio | Healthcare+ B2B｜taiwan-healthcare.org｜2026-10-08｜https://www.taiwan-healthcare.org/en/news-detail?id=0socwy3nnjfogkkr
4. PT401 Stage B1 MMVD Pilot Study at Chulalongkorn University, Thailand | Protect Biotech｜protectvac.com｜2026-10-08｜https://www.protectvac.com/en/news-detail.html?id=43
5. Protect Biotech PT401 Gene Therapy Gains Recognition from Global Animal-Health Major; Strategic Collaboration with MSD Animal Health｜protectvac.com｜2026-10-08｜https://www.protectvac.com/news-detail.html?id=43
6. ACVIM Consensus Guidelines for the Diagnosis and Treatment of Myxomatous Mitral Valve Disease in Dogs | Journal of Veterinary Internal Medicine｜pmc.ncbi.nlm.nih.gov｜2026-10-08｜https://pmc.ncbi.nlm.nih.gov/articles/PMC6524084/
7. Veterinary Cardiology Market Size, Share & Trends Analysis Report, 2026-2035 | Nova One Advisor｜novaoneadvisor.com｜2026-10-08｜https://www.novaoneadvisor.com/report/veterinary-cardiology-market
8. Asia Pacific Veterinary Cardiology Market Size & Outlook | Grand View Research｜grandviewresearch.com｜2026-10-08｜https://www.grandviewresearch.com/horizon/outlook/veterinary-cardiology-market/asia-pacific
9. Companion Animal Cardiac Drugs Market Size, Share & Trends Analysis Report, 2033 | Grand View Research｜grandviewresearch.com｜2026-10-08｜https://www.grandviewresearch.com/industry-analysis/companion-animal-cardiac-drugs-market-report
10. Asia Pacific Companion Animal Cardiac Drugs Market Size & Outlook, 2033 | Grand View Research｜grandviewresearch.com｜2026-10-08｜https://www.grandviewresearch.com/horizon/outlook/companion-animal-cardiac-drugs-market/asia-pacific
11. FDA Approves First Drug to Delay Congestive Heart Failure in Dogs | U.S. Food and Drug Administration｜fda.gov｜2026-10-08｜https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-drug-delay-congestive-heart-failure-dogs
12. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study | Journal of Veterinary Internal Medicine｜pubmed.ncbi.nlm.nih.gov｜2026-10-08｜https://pubmed.ncbi.nlm.nih.gov/27678080/
13. PT401 Dual-Gene AAV Gene Therapy for Canine Heart Disease | National Innovation Award｜innoaward.taiwan-healthcare.org｜2026-10-08｜https://innoaward.taiwan-healthcare.org/award_detail.php?REFDOCID=0t8yaf32esblr8rc&REFDOCTYPID=0mge2pv6fmqrxoa1&num=1
14. Rejuvenate Bio Announces Data for Gene Therapy RJB-01 in Mitral Valve Disease at the 2023 ASGCT Annual Meeting | Business Wire｜businesswire.com｜2026-10-08｜https://www.businesswire.com/news/home/20230518005611/en/Rejuvenate-Bio-Announces-Data-for-Gene-Therapy-RJB-01-in-Mitral-Valve-Disease-at-2023-Meeting-of-the-American-Society-of-Gene-and-Cell-Therapy-ASGCT
15. Merck & Co., Inc. 2025 Form 10-K and Full-Year Financial Results | Merck｜merck.com｜2026-10-08｜https://www.merck.com/wp-content/uploads/sites/124/2026/02/MRK-12.31.2025-10K-FINAL.pdf